Finance

Our latest numbers crunch on biopharma financial performance—this one assessing growth and value-generation during the heart of COVID-19—reveals a mix of the familiar and new entrants into the top spots in seven business-critical metrics.

While Q3 numbers look bleak, is improvement on the horizon?

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.

With large M&A deals comes a complex Market Authorization Transfer (MAT) process, during which regulatory teams must weigh several operational aspects while creating a roadmap that takes them into account. Cecile Riboud outlines some key questions that are necessary for planning and executing a successful MAT process.

But could there be a shift in momentum?

Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.

A remarkable run indeed, but cost questions can’t be ignored.

What are the reasons behind the slump and what does the future hold?

The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.

With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.

Adding context to Pfizer’s orbit-busting, first-quarter earnings.

The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?

More capital gains and the potential strains for rest of 2021.

Report provides comprehensive look at financial and accounting issues faced by life sciences industry.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Amid vaccine heroics, its complex story may finally be resonating.

Dueling paths leave market fortunes uncertain.

Tone still set on the market catalysts to look for in 2021.

Vaccine strides, likely pricing impasse point to optimism for 2021.

Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.

Biopharma raises an unprecedented $100 billion.

When the people are the sole assets.

The key factors behind the sector’s strong surge in new equity fundraisings.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

Our latest review of biopharma financial performance reveals solid growth rates in enterprise value and rebounding value-to-sales numbers—proving once again the business imperative of regaining and sustaining shareholder value.

Latest reform brouhaha requires a united response focused on real solutions.

Now is the time, the world is listening.

Rocked by pandemic, can companies protect their bottom line?

Healthy companies with coherent integration strategies will benefit from applying six lessons to ensure successful integration, writes Mark Bouch.